Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 9/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19280541 | 0.95 | PDE2A (0.39) | PDE1BPDE2ARIPK1MBOAT4MEN1 | |
| SCHEMBL21199274 | 0.81 | PDE2A (0.41) | PDE1BPDE2AMEN1ALDH1A1KMT2A | |
| SCHEMBL22055764 | 0.80 | PDE2A (0.43) | PDE1BCSF1RPDE2AMEN1ALDH1A1 | |
| SCHEMBL19280466 | 0.79 | PDE2A (0.41) | PDE1BPDE2AMEN1ALDH1A1GAA | |
| SCHEMBL19701834 | 0.79 | CSF1R (0.41) | PDE1BCSF1RPDE2AMEN1ALDH1A1 | |
| SCHEMBL21199627 | 0.77 | PDE2A (0.44) | PDE1BPDE2AMBOAT4MEN1ALDH1A1 | |
| SCHEMBL21199702 | 0.75 | LMNA (0.38) | CSF1RPDE2AMBOAT4MEN1ALDH1A1 | |
| SCHEMBL14654970 | 0.75 | GAA (0.40) | PDE1BPDE2AALDH1A1GAAMAPT | |
| SCHEMBL21199277 | 0.75 | KDM4E (0.39) | PDE1BPDE2AMEN1ALDH1A1GAA | |
| SCHEMBL14652251 | 0.73 | GAA (0.38) | PDE1BPDE2AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | PDE1B 1920/4885CSF1R 1422/4885PDE2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.